Ten Years to Dapagliflozin Metformin FDC Approval in India - 10 Key Points to Revisit

Type 2 diabetes mellitus (T2DM) affects an estimated 589 million adults globally, with India accounting for nearly 89.8 million cases, making early and durable glycaemic control a major clinical priority. Recent guidelines increasingly advocate consideration of early combination therapy to address the multifactorial pathophysiology of T2DM. In this therapeutic context, we revisit the widely used dapagliflozin–metformin fixed-dose combination, which has been available for nearly a decade since its DCGI approval on October 16, 2017. The dapagliflozin–metformin FDC has also received regulatory approval in 61 countries, including the United States, European Union, and Japan, reflecting its broad global regulatory acceptance for T2DM management. It has since accumulated substantial evidence across glycaemic, metabolic, cardiovascular, and renal outcomes. ^1-4

This article revisits 10 key evidence-based aspects of dapagliflozin–metformin FDC that remain relevant to contemporary T2DM management.

1. Complementary Multisystem Actions

Dapagliflozin, an established SGLT2 inhibitor, and metformin exert complementary mechanisms that extend beyond glucose lowering. While metformin suppresses hepatic gluconeogenesis and improves insulin sensitivity, with central glucose-regulating mechanisms established more recently; dapagliflozin promotes insulin-independent urinary glucose excretion by inhibiting renal SGLT2 receptors. Additionally, dapagliflozin reduces body weight and blood pressure, restores tubuloglomerular feedback, lowers intraglomerular pressure, and favorably influences cardiovascular hemodynamics, providing mechanistic support for its established cardiorenal protective effects. ^{5, 6}

2. Robust and Durable Glycaemic Control

The glucose-lowering efficacy of dapagliflozin–metformin has been established in both initial combination and long-term add-on therapy settings. In two pooled, randomized, double-blind, 24-week trials involving 1,236 treatment-naïve patients with T2DM (baseline HbA1c 7.5–12%), Henry et al. demonstrated that dapagliflozin (5/10 mg) plus metformin XR (up to 2,000 mg/day) reduced HbA1c by up to 2.05%, significantly outperforming either monotherapy. ⁷ In the 102-week, randomized, placebo-controlled Bailey et al. trial involving 546 patients inadequately controlled on metformin (≥1,500 mg/day), add-on dapagliflozin (2.5–10 mg) produced sustained HbA1c reductions of up to 0.78% and fasting plasma glucose reductions of up to 26.5 mg/dL versus placebo, confirming durable glycaemic efficacy. ⁸

3. Sustained Weight and Adiposity Reduction

Beyond glycaemic control, dapagliflozin provides sustained benefits in body weight and adiposity. In a randomized, double-blind, placebo-controlled study of 140 patients with T2DM inadequately controlled on metformin, dapagliflozin 10 mg/day added to metformin for 102 weeks produced sustained weight loss and reduced adiposity. Mean body weight decreased by 4.54 kg, while waist circumference declined by 5.0 cm. Importantly, total body fat mass measured using DXA decreased by 2.80 kg, indicating that the observed weight reduction was accompanied by a meaningful reduction in body fat. ⁹

4. Blood Pressure Lowering Effect in T2D

Hypertension affects more than half of adults with T2DM, substantially increasing cardiovascular and renal risk, making blood pressure control an integral component of diabetes management. In the multi-centre, retrospective ADMIRE study, 485 Indian patients with T2D received dapagliflozin–metformin FDC as initial combination therapy. After 6 months, mean systolic and diastolic blood pressure decreased by 9.9 and 6.5 mmHg, respectively. Among patients with T2D and hypertension, the corresponding reductions were 10.9 and 7.1 mmHg, with both changes reaching statistical significance, supporting favourable real-world blood pressure effects. ¹⁰

5. Reduction in Hepatic Steatosis in T2D

Hepatic steatosis is increasingly recognized as a common metabolic complication of T2DM, contributing to progressive liver and cardiometabolic disease. In a randomized, double-blind, placebo-controlled study involving T2DM patients (n=32) receiving stable background therapy, including metformin, dapagliflozin 10 mg for 8 weeks significantly reduced liver fat content measured by MRI-proton density fat fraction by 3.74% compared with placebo. Significant reductions in liver volume and visceral adipose tissue were also observed, supporting its favourable effects on ectopic fat deposition. ¹¹

6. Established Safety and Tolerability

Dapagliflozin–metformin demonstrated a favourable safety profile across clinical and real-world settings. In pooled 24-week randomized trials involving 1,236 treatment-naïve patients, hypoglycaemia was infrequent and no major episodes were reported with initial combination therapy. In the multi-centre, retrospective ADMIRE study of 485 Indian patients treated for 6 months, genitourinary infections occurred in 8.9%, while no other severe adverse events were reported, supporting good overall tolerability. ^`10

7. Dapagliflozin - Metformin: Indian Real-World Evidence

The multi-centre, retrospective ADMIRE study evaluated dapagliflozin–metformin fixed-dose combination as initial therapy in 485 Indian adults with T2DM across 48 centres over 6 months. Treatment resulted in significant improvements in HbA1c (−2.14%), fasting plasma glucose (−21.4 mg/dL) and postprandial glucose (−37.1 mg/dL), along with reductions in body weight (−4.2 kg) and blood pressure (−9.9/−6.5 mmHg). Physicians also reported good treatment compliance in 88.9% of patients, supporting the effectiveness and practicality of dapagliflozin metformin FDC in routine Indian clinical practice. ¹⁰

8. Cardiorenal Outcome Benefits Associated with Dapagliflozin

Beyond glycaemic control, the dapagliflozin component has demonstrated cardiorenal benefits in landmark outcome trials. In DECLARE–TIMI 58, 17,160 patients with T2DM followed for a median of 4.2 years experienced a 17% lower relative risk of cardiovascular death or heart-failure hospitalization (HR 0.83; 95% CI 0.73–0.95). ¹² DAPA-HF reported a 26% relative risk reduction in worsening heart failure or cardiovascular death (HR 0.74; 95% CI 0.65–0.85), ¹³ while DELIVER showed an 18% relative risk reduction in worsening heart failure or cardiovascular death (HR 0.82; 95% CI 0.73–0.92). ¹⁴ DAPA-CKD demonstrated a 39% relative risk reduction in sustained kidney-function decline, kidney failure, or cardiovascular/renal death (HR 0.61; 95% CI 0.51–0.72). ¹⁵ A subsequent lifetime time-to-event analysis projected that dapagliflozin could delay kidney failure by approximately 6.6 years compared with standard therapy. ¹⁶

More recently, a 36-month prospective real-world cohort study involving 1,231 patients with HfrEF reported that dapagliflozin was associated with significantly lower adjusted odds of MACE (adjusted OR 0.46; 95% CI 0.30–0.67) and heart failure hospitalization (adjusted OR 0.52; 95% CI 0.33–0.80) than empagliflozin, providing additional real-world evidence supporting the cardiovascular effectiveness of dapagliflozin. ¹⁷

Collectively, these study findings establish dapagliflozin as a therapy that extends benefits beyond glucose lowering to heart and kidney protection.

9. Gut Microbiome Modulation & Cardiovascular Protection Associated with Metformin

Metformin exerts pleiotropic cardiometabolic benefits beyond glycaemic control through modulation of the gut microbiota. Emerging evidence indicates that metformin enriches beneficial taxa such as Akkermansia muciniphila and SCFA-producing bacteria, enhances intestinal barrier integrity, modulates bile acid and GLP-1 signalling, and suppresses TMAO- and NF-κB-mediated inflammation. These microbiome-mediated mechanisms may potentially improve endothelial function, attenuate atherosclerosis, and contribute to the established cardiovascular benefits of metformin in T2DM. ¹⁸

10. Early Initiation for Vascular Benefits in Newly Diagnosed T2D – Newer Mechanism Unfold

Early initiation of dapagliflozin-based therapy may confer benefits beyond glycaemic control. In a 12-week, randomized, parallel-group trial just recently published in July 2026, 60 treatment-naïve adults with newly diagnosed T2DM were assigned to dapagliflozin, metformin, or dapagliflozin–metformin combination therapy. Although endothelial function and arterial stiffness were comparable between groups, dapagliflozin demonstrated significantly greater reduction in carotid intima-media thickness than metformin (adjusted mean difference −0.058 mm; 95% CI −0.106 to −0.010; p=0.018), accompanied by favourable sphingolipid and proteomic changes suggestive of early vascular protection in T2D. ¹⁹

Key Takeaways

Over nearly a decade of clinical use in India, dapagliflozin–metformin fixed-dose combination has accumulated robust evidence supporting its efficacy, durability, safety, and cardiometabolic benefits. Randomized trials, landmark outcome studies, and Indian real-world evidence consistently demonstrate improvements in glycaemic control, weight, blood pressure, hepatic steatosis, and long-term cardiorenal outcomes, reinforcing its role as an early initial consideration in contemporary T2DM management.

Abbreviations

T2DM: Type 2 Diabetes Mellitus; SGLT2: Sodium–Glucose Cotransporter-2; FDC: Fixed-Dose Combination; HbA1c: Glycated Hemoglobin; FPG: Fasting Plasma Glucose; PPG: Postprandial Plasma Glucose; DXA: Dual-Energy X-ray Absorptiometry; MRI-PDFF: Magnetic Resonance Imaging–Proton Density Fat Fraction; BP: Blood Pressure; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; CV: Cardiovascular; HF: Heart Failure; CKD: Chronic Kidney Disease; HR: Hazard Ratio; DCGI: Drugs Controller General of India; HFrEF: heart failure and reduced ejection fraction; MACE: major adverse cardiovascular events